CD274 and bladder transitional cell carcinoma: As the landmark developments of immune checkpoint inhibitors (represented by anti-PD-1/PD-L1 antibodies), Immunotherapy is playing an increasingly important role in the treatment of BLCA (Powles et al., 2014; Pettenati and Ingersoll, 2018; Rouanne et al., 2018).